Dianthus Therapeutics initiates Phase 2 trial for Claseprubart in multifocal motor neuropathy
Dianthus Therapeutics is conducting Phase 2 clinical trial to assess Claseprubart's safety and efficacy in adults with multifocal motor neuropathy.
Therapeutic Area
Therapeutic area intelligence for Multifocal Motor Neuropathy with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.